Search

everythinglearnresearchcommunity

for

Search:↓

Topical diazoxide may be a promising hair regrowth treatment, especially for those who don't respond to minoxidil, as it activates potassium channels without needing sulfation. It appears safe for topical use, avoiding systemic effects seen in oral use.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The conversation discusses the effects of lowering DHT on hair loss and the importance of monitoring DHT levels during treatment. The user suggests that individual responses to DHT and hair loss treatments vary, and expresses a preference for topical treatments over oral medications due to concerns about systemic DHT reduction.

Mesotherapy Dutasteride is considered highly effective for reducing scalp DHT and potentially reversing hair loss. However, one user reported systemic side effects and no improvement in hair loss.

Topical dutasteride with microneedling and mesotherapy dutasteride injections are effective treatments for androgenetic alopecia in both men and women. These methods offer promising alternatives to oral therapies with potentially fewer systemic side effects.

RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

The user is exploring topical Saw Palmetto as a milder alternative to microdosing topical Finasteride for hair loss, aiming to minimize systemic DHT impact. They plan to experiment with this herbal remedy for a year to assess its effectiveness on their mild androgenetic alopecia without significant side effects.

Hair loss recovery using estrogen and anti-androgen treatment for 18 months showed significant improvement. However, results vary and alternative treatments like RU58841 and Dutasteride may work without systemic feminization.

User started using topical spironolactone on scalp and face, experienced fever feeling and sluggishness. Asks if side effects are normal or systemic.

Topical retinol does not affect hair loss and may help hair regrowth. It is different from isotretinoin, which can cause hair loss due to its systemic effects.

Treatments for hair loss, including topical dutasteride minoxidil, tretonin, dermarolling, serioxyl, and redensyl over a period of 3 months; switching from RU58841 to pyrilutamide was suggested with potentially less risk of systemic side effects; and encouragement to not give up hope.

A user's experience with using 5AR inhibitors (Finasteride and Dutasteride) in combination with Minoxidil foam and microneedling, which resulted in substantial improvements to their crown density and hairline, despite high systemic levels of testosterone and dihydrotestosterone.

A user found that antihistamines stop their hair loss and related symptoms, but they experience side effects like sedation and chest pain. They are seeking alternative solutions or topical antihistamines to avoid systemic side effects.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

The conversation discusses using topical dutasteride from minoxidilmax for hair loss and the possibility of crowdfunding for DHT blood tests to check if the treatment goes systemic. The user plans to post before and after pictures.

A user shared their experience with microneedling and minoxidil for hair loss, avoiding finasteride due to concerns about systemic hormone effects. They reported slight hair regrowth after one month and plan to continue the regimen, noting improvements in skin sensitivity and managing dandruff with anti-dandruff shampoo.

A 19-year-old with diffuse hair thinning and erectile dysfunction is considering starting Propecia (finasteride) while already using a minoxidil solution with anti-androgens. Concerns are raised about the psychological nature of erectile dysfunction and the potential systemic effects of anti-androgens, with suggestions to address porn addiction and consult a doctor about hormone therapy.

The user is dissatisfied with the results of using 0.3% finasteride and 6% minoxidil for hair thinning and is considering a topical treatment combining finasteride, dutasteride, minoxidil, melatonin, caffeine, and latanoprost. Another user suggests that high topical concentrations can lead to systemic exposure and recommends using oral dutasteride and microdosing topical finasteride.

A 17-year-old is using topical minoxidil for hair loss and is considering other treatments like ketoconazole shampoo and saw palmetto while waiting to start finasteride at 19. Suggestions include using oral minoxidil, topical antiandrogens like RU58841, and CB-03-01, with a focus on minimizing systemic DHT impact.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

The user experienced significant hair regrowth over a year using topical finasteride (0.1%) and minoxidil (7%), along with Ketoconazole shampoo, and recently switched to dutasteride and plans to add oral minoxidil. They managed side effects like oily skin and itchiness with a corticosteroid and chose topical treatments initially to limit systemic exposure.

Oral minoxidil is claimed to be more effective and easier to use than topical minoxidil, with a 100% response rate, but it may cause unwanted body hair growth and has potential heart-related side effects. Topical minoxidil is less effective for many due to enzyme limitations, can cause scalp issues, and is more challenging to apply, but it avoids systemic side effects.

The conversation is about a person's hair loss treatment regimen, which includes Minoxidil, low-dose Finasteride, Pyrilutamide, weekly use of a derma roller, and hair loss shampoo. They chose these treatments to minimize systemic effects and plan to share their results for others' benefit.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

A user suggests that a .25% topical finasteride solution could reduce scalp DHT levels without affecting bloodstream DHT levels, potentially avoiding sexual side effects. They question why a 2.5% solution was chosen and if a custom .25% solution can be ordered.